This document discusses neutropenia and febrile neutropenia in children. It defines neutropenia as a decrease in absolute neutrophil count and describes different levels of severity from mild to profound. It outlines common causes of infection in febrile neutropenic children including bacteria, fungi, and viruses. Risk factors for serious infection are described. Guidelines are provided for evaluation, treatment including antibiotic and antifungal selection, and risk stratification of febrile neutropenic children.
2. Definition- decrease in the number of absolute neutrophil
count (ANC) in peripheral blood.
Absolute neutrophil count(ANC)= mature granulocytes +
neutrophil band cells.
Neutrophil count must be stratified for age and race.
• At birth predominant but rapidly decrease in first few
days of life.
• Infancy 20-30% of TLC
• At 5 yrs equal number of neutrophils and lymphocytes
count
• In adults characteristic 70% predominance of neutrophils
is usually attended during puberty.
3. For white children lower limit of normal for ANC is
1500/ cu mm while
For black children its 1200/ cu mm.
Mild neutropenia - ANC 1000 - 1500/ cu mm
Moderate neutropenia – ANC 500 – 1000/ cu mm
Severe neutropenia – ANC <500/ cu mm
Agranulocytosis – ANC <200/ cu mm
Profound neutropenia – ANC<100/ cu mm
Prolonged neutropenia – lasting >7 days
4. The relative lower limit of normal in blacks likely
reflects the prevalence of the Duffy negative (Fy-/-)
blood group, which is selectively enriched in
populations in malaria belt of Africa and is associated
with ANCs 200-600/ cu mm less than those who are
Duffy positive.
5. Development of fever in a neutropenic patient.
Defined as single oral/axillary temperature >38.3˚C
(101˚F) or two consecutive temperature >38˚C (100˚F)
in a 12 hr period for at least 1hr with ANC <500/cu mm
or <1000 cu mm with expected decline to <500/cu mm
during the next 48 hrs.
6. Common in children on chemotherapy and the most
common oncologic emergency.
The risk of infection is clearly increased when ANC drop
below 1000/mm3, with a marked increase when the ANC is
below 500/mm3.
Neutropenic patient can have serious life threatening
infections even in the absence of fever and may not present
with any localizing symptoms and signs of infection such as
exudate, fluctuance and regional lymphadenopathy,
sometimes only fever remain the only consistent early sign.
7. Approximately 48 to 60% patients who become febrile
have an established or occult infection.
Common sites of infection are the alimentary tract (i.e.,
mouth, pharynx, esophagus, large and small bowel and
rectum), perirectal abscess, sinuses, throat, ear (otitis
media), lungs and skin( cellulitis, furunculosis).
Catheter and IV sites are potential source of infection.
8. Gram positive bacteria -
Staphylococcus spp. (e.g. S. epidermidis and S. aureus)
Streptococcus spp. (alpha-hemolytic; e.g., S. mitis)
Enterococcus spp. (e.g. E. faecium, E. faecalis)
Clostridium spp. (C. difficile, C. septicum, C. tertium)
Gram-negative bacteria-
Enterobacteriaceae (E. coli, Klebsiella spp., Enterobacter
spp.)
Pseudomonas aeruginosa and
Stenotrophomonasmaltophilia
Anaerobes (e.g. Bacteroides spp. and Prevotella spp.)
9. Fungi-
Candida spp. (e.g. C. albicans, C. glabrata, C.
tropicalis, C. krusei)
Aspergillus spp. (e.g. A. fumigatus, A. flavus, and A.
terreus)
Fusarium spp. (e.g. F. solani and F. oxysporum)
Cryptococcus neoformans
Pneumocystis jiroveci (formerly, P. carinii)
12. History
Fever -onset, duration and severity
Associated localizing symptoms: Ear, nose, throat,
respiratory, gastrointestinal tract, musculoskeletal and
urinary system.
Phase of chemotherapy (intensive vs. non intensive)
Duration since the last chemotherapy
Recent hospitalization and antibiotics received, if any
13. Examination
Vitals- in every patient of suspected febrile
neutropenia, the patient may appear well despite being
in a state of hemodynamic compromise.
Detailed physical examination focusing on possible
sites of infection must be undertaken. Sites that are
commonly overlooked include oral cavity, ear, sinuses,
skin, nails, perianal area, intravascular catheter
insertion site and the site of bone marrow aspiration.
14. Investigations
First line investigations- to be performed in every case
(1).Complete blood count, including differential leukocyte count and
ANC
(2). Serum electrolytes, urea and creatinine
(3). Blood culture: Obtain as early as possible and always before the
administration of antibiotics. Two sets of blood cultures from separate
venipuncture sites should ideally be drawn. In the presence of a
central venous catheter, a blood culture should be obtained from each
lumen of the catheter and another from peripheral vein.
(4). Chest radiograph: mandatory for all, initial x-ray may be non
informative but must be taken as a baseline for comparison with later
films.
(5). Cultures from any other site, as clinically relevant. This includes
stool, urine, cerebrospinal fluid, skin, respiratory secretions or pus.
15. Second line investigations- Dictated by the clinical course:
(1).CT scan of chest/paranasal sinuses may be indicated in
patients with suspected fungal infection.
(2).Bronchoalveolar lavage: If pneumonia is non-resolving/
non-responding.
(3).Skin biopsy, from skin nodules, if any.
Despite advances in diagnostic methods, infection is
documented only in 30-40% patients.
16. Risk stratification is crucial in determining the
appropriate-
Choice of antimicrobials,
Route of administration (intravenous vs. oral),
Setting (inpatient vs. outpatient) and
Duration.
The patients can be classified as low or high risk
17. Low risk High risk
Neutropenia expected to resolve in
about 7 days
Indicators:
• Afebrile for 24hrs
• Clinically well, hemodynamically
stable
• Sterile blood culture
• Control of local infection
• Evidence of bone marrow recovery
with rising polymorphs count/
platelets/ ANC
• Non-intensive phase of
chemotherapy e.g., maintenance
phase of chemotherapy
• Malignancy in remission
• ANC≥100/mm3 and likely to rise
within the next 7 d.
Neutropenia >7days
Indicators
• Fever persisting
• Culture positive
• No evidence of bone marrow
recovery
• Recent intensive chemotherapy
• Profound neutropenia (ANC<100
cells/mm3), anticipated to extend
for >7 d.
• Evidence of hypotension,
respiratory distress or hypoxemia.
• Mucositis interfering with oral
intake or resulting in diarrhea
18. Presence of fever >39˚C, associated hypotension, ANC<100
cu mm, duration of neutropenia >7days frequently
associated with bacteremia.
Santolaya, et al found serum CRP more than 90 mg/L,
hypotension, relapsed leukemia, platelet count less than
50,000/mm3 and recent chemotherapy to be useful predictors
of serious bacterial infection.
Klaassen et al found an absolute monocyte count less than 100
cell/mm3, co-morbidity and abnormal chest radiograph to
correlate with high risk for significant bacterial infection.
For adults- the Multinational Association of Supportive Care
in Cancer (MASCC) score is used for risk stratification.
Patient with score with ≥21 are at lower risk of complications.
19. General considerations-
Pro- active steps must be taken to reduce incidence of
hospital acquired sepsis.
Barrier nursing practise- frequent hand washing, the
use of alcohol based hand rub in between patients and
wearing gloves must be ensured .
Use of IV fluids, central lines, foley’s catheter etc. must
be restricted, if possible.
20. Administration of IV fluids for minor reasons should be
avoided.
Nasogastric feeding should be encouraged in patients with
anorexia or mucositis.
Rectal enemas, suppositories, and rectal examinations are
contraindicated in neutropenic patients
High-risk’ patients are to be hospitalized and administered
broad-spectrum intravenous antibiotics
Empirical treatment should begin as soon as possible, even
before the results of cultures are available.
21. Important considerations during initial empirical
therapy-
• Risk stratification
• Any focal signs and symptoms, site of infection (e.g.,
lung)
• Antimicrobial susceptibilities of local pathogens
• Recent hospitalization, recent antibiotic exposure or
prophylactic drugs
• Past history of infection (especially fungal or resistant
bacterial such as ESBL or MRSA infection)
• Most common potentially infecting organism based on
type of immune defect
• Co-morbid conditions.
22. Care-takers are advised not to administer paracetamol
at home as it may mask fever and can lead to delay in
seeking medical care.
Administer the first dose of antibiotics without any
delay. Delay in initiating antimicrobials significantly
increases the morbidity and mortality.
23. Anti-pseudomonal agents-
penicillin (piperacillin-tazobactum), antipseudomonal
cephalosporin (cefoperazone-sulbactum) or
carbepenems (meropenem or imipenem-cilastatin) or
cefepime is recommended as first line by Infectious
Disease Society of America
BUT
no significant differences in treatment failure, including
antibiotic modification, infection-related mortality, or
adverse events were observed while comparing anti-
pseudomonas penicillin± aminoglycoside regimen with
carbapenem monotherapy in a recent meta analysis.
24. Empirically combination of antipseudomonal
antibiotic (ceftazidime, cefaperazone/ salbactam) + an
aminoglycoside is used as first line choice.
Switch to second line drugs: Vancomycin and
Carbepenems (meropenem or imipenem-cilastatin)
after 48–72 h, if fever is unrelenting and there is no
improvement in the clinical condition.
Colistin- reserved as a third line drug.
If the cultures yield a specific pathogen, the regimen
should be modified accordingly
For low risk FN oral amoxicillin- clavulinate with
ofloxacin OR cetrioxone with amikacin
25. Indications for need of vancomycin in initial regimen if
patient has -
• Hypotension or evidence of septic shock
• Obvious catheter related infection
• H/O colonization with MRSA
• High risk for viridans streptococci (severe mucositis/ AML /
prior use of quinolone prophylaxis).
If indwelling line insitu or no response in 48 hrs
antistaphylococcal antibiotic should be added.
If fever persist for 4-5 days antifungal (eg. Amphotericin
B) should be added.
Discontinuation should always be kept in mind to minimize
development of bacterial resistance
26. Add antistaphylococcal drug and if febrile at 4-5 days add antifungal
Febrile neutropenia
Initial evaluation
Physical examination
investigations
Start treatment
Ceftazidime + amynolycoside
iv
Monitor
-Fever
-ANC
Febrile afetr48hrs Afebrile
27. Afebrile
ANC>500/cu mm ANC<500/cu mm
Low risk High risk
Stop
therapy
when
afebrile
for
>48hrs
Switch to
oral
antibiotic
Low risk High risk
Give oral
antibiotic
for 7 days
Continue
antibiotic
for 10-14
days
28. If fever takes long to respond , the cultures are positive
or ANC is <100/cu mm on admission antibiotics are
given for 10-14 days or till ANC increases >500/cu
mm.
P. jiroveci can cause pneumonia regardless of
neutrophil count, prophylaxis with trimethoprim-
sulfamethoxazole against PCP is an effective
preventive strategy and should be provided to all
children undergoing active treatment for malignancy.
29. Hematopoietic growth factor-
G-CSF (Filgrastim) @5mcg/kg/day in addition to
antibiotics is useful in children with complicated febrile
neutropenia (pneumonia, hypotension, invasive fungal
infection or multi organ dysfunction), it results in-
• more rapid neutrophil recovery
• relatively fewer days of antibiotic use
• Shortens length of hospital stay
• Reduces mortality and morbidity
But G-CSF has no role in the management of children
with uncomplicated febrile neutropenia.